undamentalytics Newsletter
Sign in

Iovance Biotherapeutics, Inc. revenue

Iovance Biotherapeutics, Inc.'s revenue was $264m in fiscal 2025, up 60.6% on the year before. Over the last twelve months it was $325m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue0000001164264325
Growth on the year before———————+>999%+60.6%—
Gross profit——————07190157

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Amtagvi $220M 83.5% ▲ 112.4%
Proleukin $43.5M 16.5% ▼ 28.1%
Geography
Region Revenue Share YoY
United States $259M 98.3% ▲ 60.8%
Outside the US $4.5M 1.7% ▲ 48.3%

From Iovance Biotherapeutics, Inc.'s 10-K filed February 24, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Iovance Biotherapeutics, Inc. $325m 34.5% —
Arvinas, Inc. $317m -15.0% 26.1%
Adaptive Biotechnologies Corp $308m 50.1% 17.6%
Vericel Corp $306m 23.0% 19.8%
Vir Biotechnology, Inc. $303m 1495.9% -14.8%
Syndax Pharmaceuticals Inc $290m 159.7% 177.8%

Compare with peers

Head to head: ARVN vs IOVAADPT vs IOVAIOVA vs VCEL

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Iovance Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Iovance Biotherapeutics, Inc.